Figure 3.

Immunogenicity of LSDV-SARS2-S,N in mice. (A) Schematic of the timing of immunizations and blood draws. (B) Frequency of antigen-specific T cells recognizing SARS-CoV-2 peptide pools. (SFU, spot-forming units). (C) Quantification of spike-specific antibodies by ELISA over the course of the experiment. The antibody titers are presented for pooled sera at each time point. (D) Terminal neutralizing antibody titers against the matched virus from which the vaccines were derived. (ID₅₀, half maximal inhibitory dilution).